The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, was an exciting one for multiple myeloma (MM) data. In this interesting interview, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, speaking from the meeting, discusses the highlights for MM. With an emphasis on data from the UK, Prof. Jackson highlights the results of specific trials, including Myeloma XI (NCT01554852), and the inclusion of patients with a poorer performance status in these trials.
